Indeed, both ipilimumab (a fully human monoclonal antibody that blocks CTLA-4 to promote antitumor immunity) and vemurafenib (a potent inhibitor of mutated V600E BRAF) have been recently approved in Europe and the US for the treatment of metastatic melanoma. This evidence concerns the gene BRAF and metastatic melanoma.